Key facts
- It has raised $22.9M; the latest was Later Stage VC ($14.5M) in Jan 2025.
- Notable investors include European Innovation Council, CDP Venture Capital (Rome), Panakes Partners, Alessia Zanelli, EASME - EU Executive Agency for SMEs — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Tensive
- ·The full record, as it builds
Funding rounds
No funding rounds for Tensive are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Tensive
Developer of vascularized biodegradable prostheses designed to offer a natural breast reconstruction or augmentation. The company's prostheses use porously implantable based on biodegradable synthetic biomaterials and fabricated with internal micro-channels mimicking the blood-vessels architecture for the treatment of breast cancer, enabling patients to improve their quality of life and avoid recurrent and expensive surgical operations.
- Sector
- Healthcare
- HQ
- Milan, Italy
- Founded
- 2012
- Employees
- 34
- Website
- tensive.com/
- Ownership
- Privately Held (backing)
Tensive doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Tensive shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Tensive in its N-PORT filings yet. We sweep new filings monthly.